PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 12791249

Activating MAP KAP kinase 2.

Ernst ter Haar
View original source ↗Export metadata ↓

Abstract

The crystal structures of MAP KAP kinase 2 in complex with ADP and staurosporine suggest a major reorganization of the glycine-rich loop upon ligand binding. The main determinant for the catalytic activity of MAP KAP kinase 2 is phosphorylation by p38 MAP kinase.

Explore related subjects

Adenosine DiphosphateAnimalsEnzyme ActivationIntracellular Signaling Peptides and ProteinsMitogen-Activated Protein KinasesProtein Serine-Threonine KinasesProtein Structure, TertiaryStaurosporinep38 Mitogen-Activated Protein KinasesMAP-Kinase-Activated Kinase 2NewsComment

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Ernst ter Haar. 2003. Activating MAP KAP kinase 2.. https://doi.org/10.1016/s0969-2126(03)00104-7

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2022

A novel DPH5-related diphthamide-deficiency syndrome causing embryonic lethality or profound neurodevelopmental disorder.

PURPOSE: Diphthamide is a post-translationally modified histidine essential for messenger RNA translation and ribosomal protein synthesis. We present evidence for DPH5 as a novel cause of embryonic lethality and profound neurodevelopmental delays (NDDs). METHODS: Molecular testing was performed using exome or genome sequencing. A targeted Dph5 knockin mouse (C57BL/6Ncrl-Dph5em1Mbp/Mmucd) was created for a DPH5 p.His260Arg homozygous variant identified in 1 family. Adenosine diphosphate-ribosylation assays in DPH5-knockout human and yeast cells and in silico modeling were performed for the identified DPH5 potential pathogenic variants. RESULTS: DPH5 variants p.His260Arg (homozygous), p.Asn110Ser and p.Arg207Ter (heterozygous), and p.Asn174LysfsTer10 (homozygous) were identified in 3 unrelated families with distinct overlapping craniofacial features, profound NDDs, multisystem abnormalities, and miscarriages. Dph5 p.His260Arg homozygous knockin was embryonically lethal with only 1 subviable mouse exhibiting impaired growth, craniofacial dysmorphology, and multisystem dysfunction recapitulating the human phenotype. Adenosine diphosphate-ribosylation assays showed absent to decreased function in DPH5-knockout human and yeast cells. In silico modeling of the variants showed altered DPH5 structure and disruption of its interaction with eEF2. CONCLUSION: We provide strong clinical, biochemical, and functional evidence for DPH5 as a novel cause of embryonic lethality or profound NDDs with multisystem involvement and expand diphthamide-deficiency syndromes and ribosomopathies.

Adenosine Diphosphate↗
PubMed2006

The role of ADP receptors in platelet function.

Adenine di-Phosphate (ADP) is an important physiological agonist that plays a vital role in normal hemostasis and thrombosis. The importance of ADP in normal hemostasis is clearly demonstrated in patients suffering from storage pool disease who show excessive bleeding tendencies. It is well established that ADP activates platelets through 3 purinergic receptors, namely P2Y1, P2Y12 and P2X1. The P2Y1 receptor is a Galpha q coupled G-protein receptor that is important for platelet shape change, aggregation, thromboxane A2 generation, procoagulant activity, adhesion to immobilized fibrinogen and thrombus formation under shear conditions. The availability of P2Y1 antagonists and knockout mice have aided in demonstrating the multiple functions of this receptor in platelet function and normal hemostasis. The second ADP receptor, the P2Y12 signals through a Galpha i coupled G-protein receptor and has been shown to be important for platelet functions very similar to the P2Y1 receptor. In addition, the P2Y12 receptor is also important for potentiation of platelet activation mediated by other physiological agonists including collagen, von Willebrand and thromboxane A2. Advances in understanding the importance of the P2Y12 receptor has resulted in the development of drugs like clopidogrel and ticlopidine that is being successfully used clinically in the treatment of thrombotic disorders. The understanding of the function of this receptor has been possible due to the availability of multiple P2Y12 antagonists and the development of the P2Y12 null mice. The third and the final P2X1 receptor is an ion channel that upon activation causes an influx of calcium. Even though the activation of this receptor by itself doesn't lead to aggregation, it causes shape change and aids in the activation process of other agonists. Studies have also shown that it is important for thrombus formation under shear conditions in small arteries. Signaling by this receptor leads to significant ERK activation, which has been shown, to be important for collagen mediated platelet activation. The importance of ADP in hemostasis and thrombosis greatly underscores the significance of understanding the function of these receptors that would enable development of potent and safe anti-thrombotic drugs.

Adenosine Diphosphate↗
PubMed2006

Sex differences in platelet reactivity and response to low-dose aspirin therapy.

CONTEXT: Recent randomized trials suggest that women may not accrue the same cardioprotective benefits as men do from low-dose aspirin therapy used in primary prevention. Failure of aspirin to suppress platelet aggregation in women is one hypothesized mechanism. OBJECTIVE: To examine differential platelet reactivity to low-dose aspirin therapy by sex. DESIGN, SETTING, AND PARTICIPANTS: A clinical trial of aspirin at 81 mg/d for 14 days was conducted in 571 men and 711 women. Baseline and post-aspirin therapy measures included platelet aggregation to arachidonic acid, adenosine diphosphate, epinephrine, and platelet function analyzer closure time. MAIN OUTCOME MEASURE: Sex differences in cyclooxygenase 1 (COX-1) direct and indirect platelet activation pathways before and after administration of aspirin. RESULTS: In 10 of the 12 platelet agonist exposures, women's platelets were significantly more reactive at baseline. However, after aspirin therapy, the percent aggregation to arachidonic acid (the direct COX-1 pathway) decreased more in women than in men (P<.001) and demonstrated near total suppression of residual platelet reactivity in both men and women. In COX-1 indirect pathways, women experienced the same or more platelet inhibition than men in 8 of the 9 assays yet retained modestly greater platelet reactivity after aspirin therapy. In multivariable analysis, female sex significantly predicted aggregation to 2 muM and 10 muM of adenosine diphosphate (P = .02 and <.001, respectively) and collagen at 5 mug/mL (P<.001) independent of risk factors, age, race, menopausal status, and hormone therapy. CONCLUSIONS: Women experienced the same or greater decreases in platelet reactivity after aspirin therapy, retaining modestly more platelet reactivity compared with men. However, most women achieved total suppression of aggregation in the direct COX-1 pathway, the putative mechanism for aspirin's cardioprotection.

Adenosine Diphosphate↗